Chronic Leukemia Perspective

 
 
  • NephMadness 2015: Onconephrology Learn about key concepts that overlap oncology with nephrology, and then use your knowledge to pick the 'winners' in the NephMadness Tournament.
  • CLL: It's the Best -- and Most Confusing -- of Times   Dr Bruce Cheson and Dr Susan O'Brien discuss data presented at the 2014 ASH meeting on chronic lymphocytic leukemia, with a focus on the CLL10 trial as well as ibrutinib, idelalisib, and ADT-199.
  • The Year in Hematologic Malignancies Experts in hematologic malignancies comment on the most important developments and practice-changing clinical trials of 2014.
  • ASH 2014: If You're Going to San Francisco…   Dr Bruce Cheson previews important data being presented at the upcoming ASH 2014 meeting, including studies of CLL, Hodgkin lymphoma, and the role of interim PET scans in large cell lymphoma.
  • What's New: Imaging in Lymphoma   Dr Bruce Cheson breaks down new consensus recommendations on the role of imaging in staging and response assessment for lymphoma.
  • The 'Fab Five' Rock Lymphoma   Dr Martin Dreyling reviews recent data in lymphoma indicating that the command performance of five biologic agents do all but lock the door on chemotherapy and throw away the key.
  • ESMO Guideline for Mantle Cell Lymphoma ESMO recently published its guideline for mantle cell lymphoma. Author Martin Dreyling highlights some of the key, evidence-based recommendations.
  • CAR T Cells: A Look Under the Hood and Down the Road Lost your way in immunotherapy? Dr. Mark Adler provides clinicians a roadmap for navigating cancer immunotherapy and takes one of the most promising approaches -- CAR T cells -- for a test drive.
  • CLL's 'Very Unusual Year'   Dr. Bruce Cheson discusses how to choose among the new, exciting options available for the treatment of chronic lymphocytic leukemia: obinutuzumab, ibrutinib, and idelalisib.
  • Ibrutinib Stands Center Stage in CLL   Dr. John Gribben highlights new data on single and combination therapies for CLL as presented at EHA 2014.
  • Ibrutinib Results RESONATE in Refractory CLL   Drs. Bruce Cheson and Myron Czuczman discuss lymphoma and leukemia highlights from ASCO 2014, including the RESONATE and SEXIE trials and emerging antibody-drug conjugates.
  • ASCO® 2014: Aiming at Cancer’s Achilles Heel   Four leading oncologists discuss the top studies from ASCO 2014 and how immunotherapy is reshaping cancer care and practice.
  • What to Watch in Lymphoma, Leukemia   Dr. Bruce Cheson reviews a wealth of practice-changing and practice-confirming studies from the lymphoma and leukemia sessions at ASCO 2014.
  • Mantle Cell Lymphoma -- Still More Questions Than Answers Mantle cell lymphoma remains a clinical challenge. Dr. Julie Vose discusses current evidence on treatments, differences in strategy, and whether emerging novel therapies could improve outcomes.
  • FDA Sends Valentine to CLL Patients   The FDA approval of ibrutinib is a red-letter day for patients with relapsed chronic lymphocytic leukemia, because of the drug’s quick action and effectiveness, says Dr. Bruce Cheson.
  • Idelalisib Combo Rings Bells in Relapsed CLL   Patients with relapsed chronic lymphocytic leukemia, who were less able to undergo chemotherapy, had improved OS with a combination of idelalisib and rituximab, in a study reported by Dr Bruce Cheson.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Novel Agents: Making the Benefit Last in CLL Drs. Susan O'Brien and Bruce Cheson discuss the exciting array of oral, well-tolerated, quick-acting therapies for CLL that provide durable if only partial remission.
  • Tailoring CLL Treatment to a TTT In CLL, combinations and sequences of agents are tailored to initial tumor load and response to therapy to optimize outcome, says Dr. Michael Hallek in a Medscape interview from ASH 2013.
  • CLL Combos: And the Winner Is… The question of which is better -- FRC or BR -- is settled, sort of, at ASH 2013, in a study discussed by Drs. Bruce Cheson and Clemens Wendtner.